ICU Medical (NASDAQ:ICUI) Price Target Lowered to $187.00 at Raymond James

ICU Medical (NASDAQ:ICUI) had its price objective cut by stock analysts at Raymond James from $197.00 to $187.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “strong-buy” rating on the medical instruments supplier’s stock. Raymond James’ price target points to a potential upside of 35.21% from the company’s previous close.

Other analysts have also issued reports about the stock. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Friday, May 2nd. KeyCorp dropped their price objective on shares of ICU Medical from $209.00 to $191.00 and set an “overweight” rating on the stock in a research note on Monday, April 21st. Finally, Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Tuesday, April 8th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $192.67.

ICU Medical Price Performance

Shares of ICUI stock opened at $138.30 on Friday. The company has a market capitalization of $3.40 billion, a P/E ratio of -30.26 and a beta of 0.87. The company’s 50-day simple moving average is $140.67 and its two-hundred day simple moving average is $155.13. ICU Medical has a one year low of $100.91 and a one year high of $196.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.49. The company had revenue of $599.49 million for the quarter, compared to analysts’ expectations of $574.15 million. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. ICU Medical’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.96 earnings per share. As a group, equities analysts anticipate that ICU Medical will post 4.11 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ICUI. Arizona State Retirement System increased its position in ICU Medical by 1.0% during the 4th quarter. Arizona State Retirement System now owns 6,730 shares of the medical instruments supplier’s stock valued at $1,044,000 after buying an additional 65 shares in the last quarter. Huntington National Bank grew its stake in shares of ICU Medical by 6.2% during the fourth quarter. Huntington National Bank now owns 1,402 shares of the medical instruments supplier’s stock worth $218,000 after acquiring an additional 82 shares during the last quarter. Equitable Trust Co. increased its holdings in shares of ICU Medical by 1.6% during the fourth quarter. Equitable Trust Co. now owns 5,297 shares of the medical instruments supplier’s stock valued at $822,000 after acquiring an additional 84 shares in the last quarter. Xponance Inc. raised its position in shares of ICU Medical by 5.3% in the 1st quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier’s stock valued at $238,000 after purchasing an additional 86 shares during the last quarter. Finally, LPL Financial LLC boosted its stake in ICU Medical by 2.0% in the 4th quarter. LPL Financial LLC now owns 4,816 shares of the medical instruments supplier’s stock worth $747,000 after purchasing an additional 93 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.